RESEARCH TRIANGLE PARK, N.C. – March 10, 2025 – IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the “Leaders” category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment.

IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when seeking deep clinical and DCT implementation strategy expertise across therapeutics areas and phases, with over 200 DCT consultants, a wide portfolio of DCT-enabling technologies and services, and expertise in providing inputs on country-wise regulatory strategy for DCT implementation and on business process transformation for implementing a DCT model, as well as a focus on implementing healthcare-grade AI across the value chain, with novel GenAI tools to transform patient experience.”

“Call them what you may — decentralized trials, virtual trials, hybrid trials — DCTs are here to stay,” wrote Dr. Nimita Limaye, IDC’s research VP, Life Sciences R&D Strategy and Technology. “The focus is on integration, integration of technologies, integration of touch points to create unified and meaningful experiences, and the alignment of technologies and operating models. The way the industry is perceiving DCTs is maturing. No, DCTs aren’t going away. Instead, DCTs are becoming a 'business as usual' strategy today.”

Decentralized clinical trials, which gained popularity during the COVID-19 pand…